Global Glomerular Disease Therapeutics Market – Industry Trends and Forecast to 2029

请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

Global Glomerular Disease Therapeutics Market – Industry Trends and Forecast to 2029

Global Glomerular Disease Therapeutics Market, By Indication (Glomerulonephritis, Nephropathy, Goodpasture Syndrome, Others), Treatment (Corticosteroids, ACE Inhibitors, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

  • Pharmaceutical
  • Nov 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Glomerular Disease Therapeutics Market

市场规模(十亿美元)

CAGR :  % Diagram

Chart Image USD 15.30 Billion USD 22.60 Billion 2025 2033
Diagram Forecast Period
2026 –2033
Diagram Market Size (Base Year)
USD 15.30 Billion
Diagram Market Size (Forecast Year)
USD 22.60 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Glomerular Disease Therapeutics Market, By Indication (Glomerulonephritis, Nephropathy, Goodpasture Syndrome, Others), Treatment (Corticosteroids, ACE Inhibitors, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Glomerular Disease Therapeutics Market

Glomerular Disease Therapeutics Market Analysis and Size

The global glomerular disease therapeutics market is expected to witness significant growth during the forecast period. The growth of glomerular disease therapeutics market is enhanced by the rise in cases of kidney disorder worldwide and vulnerable aging population. Furthermore, ongoing research activities related to glomerular disease therapeutics, high patient awareness level and favourable regulatory scenario are considered as positive indicator for the growth of glomerular disease therapeutics drugs

Data Bridge Market Research analyses a growth rate in the global glomerular disease therapeutics market in the forecast period 2022-2029. The expected CAGR of global glomerular disease therapeutics market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 12590.4 million in 2021, and it would grow upto USD 18,601.7 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Glomerular Disease Therapeutics Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Indication (Glomerulonephritis, Nephropathy, Goodpasture Syndrome, Others), Treatment (Corticosteroids, ACE Inhibitors, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral)), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Alkem Labs Ltd (India), Apotex Inc (Canada), WOCKHARDT (India)

Market Opportunities

  • Increased Drug Approvals
  • Increasing Demand for Retail Pharmacies

Market Definition

Glomerular disease is type of renal disorder affecting the small filtering unit of kidneys called glomeruli. It is caused by several factors such as autoimmune disorders, genetic factors, infection in other parts of the body and sclerotic diseases.  

Global Glomerular Disease Therapeutics Market Dynamics

Drivers

  • Increased Incidence of Kidney Diseases

The rising prevalence of chronic kidney disease worldwide is majorly responsible for boosting the growth of the global renal drugs market. According to the National Kidney Foundation reports, approximately 10% of the global population is affected by chronic kidney disease (CKD). Thus, it boosts the market growth.

  • Rising Demand for Oral Drugs

Oral drugs is projected to boost the market growth. The segment is anticipated to increase the global market as majority of the products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

  • Increasing Demand for Retail Pharmacies

The rise in the number of renal drugs delivered through retail pharmacies and the increase in the number of retail pharmacies in extremely developed countries create opportunities for the market growth. Additinally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

  • Side Effects of Renal Drugs

The side effects associated with these glomerular disease therapeutics could curb the growth of the global renal drugs market over a forecast period. Effects such as loss of appetite, fever, rashes, can hamper the market growth.

  • High Cost

The huge expenditure associated with these agents hamper the market growth. Several corticosteroids, ACE inhibitors, immunosuppressive therapy types are the ones that are hampering the growth of the market.

This global glomerular disease therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global glomerular disease therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Glomerular Disease Therapeutics Market Scope

The global glomerular disease therapeutics market is segmented on the basis of indication, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Glomerulonephritis
  • Nephropathy
  • Goodpasture Syndrome
  • Others

Treatment

  • Corticosteroids
  • Aristocort
  • Bubbli-Pred
  • Celestone
  • ACE Inhibitors
  • Benazepril
  • Captopril
  • Enalapril
  • Immunosuppressive Therapy
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Glomerular Disease Therapeutics Market Regional Analysis/Insights

The global glomerular disease therapeutics market is analyzed and market size insights and trends are provided by indication, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global glomerular disease therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a highest growth for global glomerular disease therapeutics market throughout the forecasted period due to increased smoking, hypertension & diabetic population, and presence of key manufacture of the prod to the high diagnostic rate and presence of key players in this region.

North America dominates the market due to the growing cases of kidney disorder, presence of sophisticated medical facilities in order to maximize the treatment effectiveness for patient suffering from glomerular disease and increases focuses in the research and development activity.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Glomerular Disease Therapeutics Market Share Analysis

The global glomerular disease therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global glomerular disease therapeutics market.

Key players operating in the global glomerular disease therapeutics market include:

  • Pfizer Inc (U.S.)
  • AstraZeneca (U.K.)
  • AbbVie.Inc (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Dr. Reddy's Laboratories Ltd (India)
  • Endo International plc (Ireland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sun Pharmaceutical Industries Ltd (India)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Lupin (India)
  • Cipla Inc (India)
  • Aurobindo Pharma (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • A Alkem Labs Ltd (India)
  • Apotex Inc (Canada)
  • WOCKHARDT (India)


SKU-

在线获取全球首个市场情报云平台的报告访问权限

  • 交互式数据分析仪表板
  • 用于发现高增长潜力机会的公司分析仪表板
  • 研究分析师支持(定制与咨询)
  • 带有交互式仪表板的竞争对手分析
  • 最新新闻、更新与趋势分析
  • 利用基准分析的强大功能,实现全面的竞争对手跟踪
申请演示

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。

常见问题

2021年全球光合作用疾病治疗市场为1.259亿美元。
2022-2029年的预测期间,全球光合作用疾病治疗市场预计增长5%。
北美由于肾脏紊乱病例增多而占据了市场主导地位,有精密的医疗设施存在,以最大限度地为患克氏病的患者提供治疗效果,并更注重研发活动.
由于吸烟、高血压和糖尿病人口的增加,以及该地区诊断率高的主要制造商的存在和主要参与者的存在,整个预测期间,亚太区域全球光合作用疾病治疗市场增长最快。
2025年全球疾病治疗市场规模价值为153亿美元。
2026-2033年预测期间,全球疾病治疗市场将增长5.0%。
根据指示、治疗、管理路线、最终用户和分销渠道,全球疾病治疗市场分为五个值得注意的部分。 根据征兆,市场被分化为光聚酮炎,肾上腺炎,Goodpasture综合征等. 在治疗的基础上,市场被分解为皮质类固醇,ACE抑制剂,免疫抑制疗法等. 根据管理路线,市场分为口述和亲述两种. 在最终用户的基础上,市场分为医院、家庭护理、专科诊所等。 根据分销渠道,市场分为医院药房,在线药房,零售药房.
Novartis AG(瑞士),F. Hoffmann-La Roche有限公司(瑞士),Pfize Inc.(美国),AstraZeneca(英国),Bristol Myers Squibb(美国)等公司是光荣疾病治疗市场的主要参与者.

行业相关报告

客户评价